KCI Milestones
2009
KCI launches ABThera™ Open Abdomen Negative Pressure Therapy (OA NPT) System, the latest addition to the Negative Pressure Technology Platform (NPTP). The ABThera™ System addresses patient quality of life through an easy-to-use system designed to assist surgeons in the management and treatment of Abdominal Compartment Syndrome (ACS) and to help achieve primary fascial closure.
KCI introduces V.A.C.® GranuFoam™ Bridge Dressing, further expanding the portfolio of dressings used in the treatment of chronic wounds. This new dressing simplifies application in chronic wounds, especially Diabetic Foot Ulcers (DFUs) where it is compatible with off-loading devices.
2008
KCI introduces the V.A.C.® Simplace™ Dressing that features both a V.A.C.® GranuFoam™ Dressing and a 3M™ Tegaderm™ Dressing designed for use with KCI's proprietary V.A.C.® Therapy System. The innovative design of the V.A.C.® Simplace™ Dressing is a direct result of extensive "voice of the customer" feedback from carers and patients, making the dressings easier, faster and more intuitive to apply.
KCI enters the regenerative medicine business by acquiring LifeCell™ Corporation, a leader in innovative tissue repair products for use in reconstructive, urogynaecological and orthopaedic surgical procedures. AlloDerm® Regenerative Tissue Matrix is used for plastic reconstructive, general surgical, burn and periodontal procedures. The company’s Strattice™ Reconstructive Tissue Matrix is used in reconstructive and general surgical procedures.
2007
KCI introduces third-generation InfoV.A.C.® and ActiV.A.C.® Therapy Systems globally which are the only TNP/NPWT systems specifically cleared for use in all care settings, including home use.
KCI establishes a global manufacturing facility in Athlone, Ireland.
2005
KCI expands into Denmark and the Middle East.
2004
KCI is listed on the New York Stock Exchange.
2001
Opening of KCI International offices in Amsterdam, the Netherlands.
2000
KCI receives approval for Medicare Part B reimbursement for V.A.C.® Therapy. This approval makes the innovative V.A.C.® Therapy System available to elderly and disabled home care patients in the United States.
Several “next-generation” V.A.C.® Therapy products are introduced.
1996
KCI launches its greatest innovation to date: the V.A.C.® Therapy System, which is clinically demonstrated to promote wound healing while reducing the overall cost of treating patients with complex wounds. During the coming years, KCI succeeds in making V.A.C.® Therapy available in several care settings.
1995
KCI introduces the most advanced support surface to date for patients with, or at risk for, pulmonary complications. KCI also introduces its first medical device, one that provides foot compression therapy to prevent deep vein thrombosis, and a device for low air loss therapy.
1990
KCI opens sales offices in Germany, France and the Netherlands.
1989
KCI opens first international sales offices in Canada and the United Kingdom.
1988
KCI launches therapeutic surfaces, TheraPulse™ Pulsating Air Suspension Therapy and FluidAir™ Air Fluidised Surface Therapy.
1977
Roto Rest® Kinetic Therapy™ System manufactured by KCI.
1976
Dr. Jim Leininger, an accident and emergency physician, purchases the manufacturing rights to a critical care bed, and with a few employees, founds Kinetic Concepts, Inc. Over the next decade, KCI develops a variety of innovative surfaces products, launching the company’s 30-year heritage of innovation.
Contact:
Kinetic Concepts, Inc.
Kevin Belgrade
Office: 210-255-6232; Wireless: 210-216-1236
media@kci1.com
This Web page contains information about products which may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use.
Updated: September 21, 2009